Providence study suggests encouraging new option for advanced melanoma
The Providence Cancer Center
has been expanded to allow up to 70 patients to enroll, after the combination of two immunotherapy treatments achieved a 77 percent disease-control rate in patients with advanced melanoma.
Brendan Curti, M.D.
, co-director of the Providence Cancer Center Melanoma Program, presented the preliminary results at the 2017 annual meeting of the American Association for Cancer Research in April.
Included in the trial were several patients who had been treated previously with immune checkpoint inhibitors
and had become resistant to the approach. The combination treatment appeared to overcome that resistance.
In addition, side effects were minimal.
Patients in the study receive both an investigational formulation of CVA21 (CAVATAK), an immunotherapy based on a common cold virus, and ipilimumab (Yervoy), an FDA-approved immunotherapy.
Of 22 patients evaluated to date, four
have had a complete response, seven
have had a partial response and six
have stable disease.
This featured study is one of 12 melanoma studies currently open at Providence Cancer Center. To see all open melanoma studies, click
To see all studies in all cancer types, click